This will probably be the last Top Three post for about a week or so, as I head out to Chicago for the SPBT (Society of Pharmaceutical and Biotech Trainers) conference. And there’s a bit of backlog today, so here goes – more than three!
Acorda shares jump after its experimental MS pill gets a priority review notice from FDA. Oral MS treatments are going to be big news over the next year…
Vanda gets approval for its schizophrenia drug. And, as is typical of atypicals, a black box warning.
Roche‘s Avastin cleared for brain cancer.
Solvay receives FDA approval for pancreas drug Creon.
Drug-coated stents – safety verified, and better at keeping arteries open.
An interesting discussion of marketing tactics (pay-for-non-performance) in Europe over osteo drugs, and the upcoming Novartis/Amgen tussle in that area.
Credibility on the commercial side of pharma marketing (Vioxx): Not. Not.
Subscribe to the Impactiviti blog via e-mail
Subscribe to the Impactiviti blog via RSS
Connect with Steve Woodruff
Leave a Reply